First Wave BioPharma Inc. (NASDAQ: FWBI) stock gained by 4.85% in the current market trading. First Wave BioPharma which is headquartered in Boca Raton Florida is a biopharmaceutical business that is focused on the development of non-systemic, tailored treatments for GI illnesses. FW-EPI (adrulipase) is also being developed by First Wave BioPharma for the cure of exocrine pancreatic insufficiency (EPI) in cystic fibrosis and persistent pancreatitis patients.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
What’s up with FWBI stock?
First Wave BioPharma announced the appointment of Brian Feaganto First Wave BioPharma’s scientific advisory board (SAB), effective immediately.
Dr. Feagan will serve on the First Wave BioPharma SAB alongside Anthony Opipari, M.D., Ph.D., Richard Marlink, M.D., and Michael Konstan, M.D. The SAB will collaborate with management to help First Wave BioPharma progress its pipeline of development and clinical-stage initiatives centred on its two gut-restricted GI innovations, niclosamide, and adrulipase.
Dr. Feagan is a gastroenterologist who specializes in IBD, such as ulcerative colitis and Crohn’s disease. His study focuses on the development and execution of controlled studies of inflammatory bowel disease therapy. More than 140 multi-center large-scale randomized clinical studies focusing on innovative IBD therapies have been conducted with him as the primary investigator.
James Sapirstein, CEO of First Wave BioPharma stated that,
They’re thrilled to welcome a clinician and researcher of Dr. Feagan’s stature to their growing list of scientific, medical, and industrial thinking leaders. It will provide expert advice to First Wave BioPharma as they advance their many pipeline programmes. Dr. Feagan’s hiring underscores First Wave BioPharma’s enhanced clinical development potential for its unique niclosamide formulations in inflammatory bowel disease areas (IBDs). Dr. Feagan’s experience with inflammatory bowel illness and his scientific skills, in particular, should benefit them in the months and years ahead.